Men age 60 and younger treated with proton therapy for prostate cancer at the UF Health Proton Therapy Institute report excellent long-term outcomes related to cure rate and health-related quality of life.
A long-term, prospective clinical study followed 254 low-, intermediate-, and high-risk prostate cancer patients for seven years. Outcomes for cancer recurrence were charted as well as incidence of side effects impacting sexual, urinary and bowel health. Results from the study were published last month in Acta Oncologica.
Median follow-up was 7.1 years and 97.8 percent of men had no evidence of cancer. Cancer-free survival was 99.2 percent and 97.7 percent for low- and intermediate-risk prostate cancer patients respectively.
Potency (erections firm enough for sexual intercourse) was 90 percent at baseline and declined to 72 percent at the first-year follow-up, but declined to only 67 percent at five years. Only two percent of patients developed urinary incontinence requiring pads. The bowel habits mean score declined from a baseline of 96 to 88 at one year, which improved over the following years to 93 at five years.
Men who are 60 years old or younger when diagnosed with prostate cancer have a life expectancy of more than 10 years. The treatment decision – most often surgery or radiation – can significantly impact quality of life depending on the risk of side effects.
“Since similar local control and overall survival have been observed for surgery and radiation, health-related quality of life has emerged as an increasing focus in men considering their treatment options. Several investigations have reported fear of incontinence was a decision-making factor in men, while a more recent study reported that younger men placed more importance on sexual function when choosing treatment options,” said Bradford S. Hoppe, MD, MPH, James E. Lockwood, Jr., Endowed Chair of Proton Therapy at the University of Florida Health Proton Therapy Institute. “Our study provides meaningful information for clinicians and patients to consider when evaluating treatment options that may minimize the risk of erectile dysfunction.”